Anti-CXCR4 antibodies and their use for the treatment of cancer

摘要

The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to the 414H5 and 515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.

主权项

1. An isolated anti-CXCR4 antibody capable of inhibiting activation of CXCR4, wherein the antibody comprises:
a light chain comprising the CDR-L1 of the sequence SEQ ID No. 1, the CDR-L2 of the sequence SEQ ID No.2, and the CDR-L3 of the sequence SEQ ID No. 3; and a heavy chain comprising the CDR-H1 of the sequence SEQ ID No. 7, the CDR-H2 of the sequence SEQ ID No.5, and the CDR-H3 of the sequence SEQ ID No. 8.